Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity.

Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. · 2019

Read Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. by Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6371029.txt.

Introduction

Romano and co-authors present a review in Frontiers in Immunology on regulatory T cell therapy. These cells keep the immune system tolerant of the body's own tissues. Giving patients extra regulatory cells could prevent graft rejection and calm autoimmune disease without heavy immune suppression.

The review covers how the cells develop, how they suppress other immune cells, and how clinics isolate and grow them. Early phase I trials in transplant and autoimmune settings showed the therapy is safe and feasible. Phase II trials are now enrolling. The authors close with strategies to make cell products purer, more stable, and more effective.

Catalog record

CREATORRomano M, Fanelli G, Albany CJ, Giganti G, Lombardi G.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6371029

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity By Marco Romano, Giorgia Fanelli, Caraugh Jane Albany, Giulio Giganti, Giovanna Lombardi Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2019.00043 ABSTRACT Regulatory T cells (Tregs) are important for the induction and maintenance of peripheral tolerance therefore, they are key in preventing excessive immune responses and autoimmunity. In the last decades, several reports have been focussed on understanding the biology of Tregs and their mechanisms of action. Preclinical studies have demonstrated the ability of Tregs to delay/prevent graft rejection and to control autoimmune responses following adoptive transfer in vivo. Due to these promising results, Tregs have been extensively studied as a potential new tool for the prevention of graft rejection and/or the treatment of autoimmune diseases. Currently, solid organ transplantation remains the treatment of choice for end-stage organ failure. However, chronic rejection and the ensuing side effects of immunosuppressants represent the main limiting factors for organ acceptance and patient survival. Autoimmune disorders are chronic diseases caused by the breakdown of tolerance against self-antigens. This is triggered either by a numerical or functional Treg defect, or by the resistance of effector T cells to suppression. In this scenario, patients receiving high doses of immunosuppressant are left susceptible to life-threatening opportunistic infections and have increased risk of malignancies. In the last 10 years, a few phase I clinical trials aiming to investigate safety and feasibility of Treg-based therapy have been completed and published, whilst an increasing numbers of trials are still ongoing. The first results showed safety and feasibility of Treg therapy and phase II clinical trials are already enrolling. In this review, we describe our understanding of Tregs focussing primarily on their ontogenesis, mechanisms of action and methods used in the clinic for isolation and expansion. Furthermore, we will describe the ongoing studies and the results from the first clinical trials with Tregs in the setting of solid organ transplantation and autoimmune disorders. Finally, we will discuss strategies to further improve the success of Treg therapy. INTRODUCTION Since the discovery in 1969 of the suppressor T cells (1), the regulatory T cells (Tregs) research field has undergone an incredible boom over the years. Studies on the biology of Tregs have attracted a lot of attention and our knowledge about their development and differentiation has increased enormously. The breakthrough in this field dates back to the discovery, in 1995, of a subset of thymus derived CD4+ T cells expressing high levels of IL-2Rα (CD25) able to protect thymectomized mice from autoimmunity (2). Since then, well-cited papers have shown the crucial role of Tregs in maintaining immune homeostasis (3) and preventing autoimmunity (4). Despite the improvement in Treg biology, nowadays there are no specific markers to characterize human Tregs. Differently from the mouse counterpart, the sole expression of CD25 and the transcriptional regulator forkhead box P3 (FOXP3) (5) is not sufficient for characterizing human Tregs, since effector T cells can upregulate these markers after activation. However, the methylation status of the Treg-specific demethylated region (TSDR) (6), a conserved non-coding element within the FoxP3 gene locus, can be used for the identification of the “real” human Tregs (7). The analysis of TSDR methylation does not represent a suitable tool for their isolation; currently the expression of CD4, CD25, and lack of the α-chain of IL-7R (CD127) (8) are used for Tregs purification. In preclinical studies, human CD4+CD25+CD127− Tregs have been shown to be effective in preventing Graft vs. Host Disease (GvHD) (9, 10), autoimmune diseases (11, 12) and delaying graft rejection (13, 14). The positive outcomes gave the rationale to apply Tregs for the treatment of human diseases and results from the first clinical trials with adoptively transferred Tregs were published in 2009 (15). Solid organ transplantation represents the only treatment for end-stage organ diseases. Over the years, several strategies have been applied in order to improve transplantation outcomes and short-term graft survival (16). A better selection of donors and recipients associated with improved immunosuppressive schemes and patients' management has been crucial for ameliorating the graft survival in early stages. Long-term organ acceptance is a different story, remaining constant over the past decades (17). The immunosuppressive regimen, consisting of a combination of different drugs, aims to dampen the response of the immune system to the graft. Although successful in controlling the immune response early post-transplant, it is linked with detrimental side effects. Cardiovascular diseases, cancer, kidney failure and infections represent the main side effects that can cause graft loss and death (18). Long-term outcomes and finally operational tolerance are key for a successful organ transplantation. Different strategies are under investigation with the aim to reduce the use of immunosuppressive drugs. In this scenario, Tregs might represent a valid solution for controlling the immune response and inducing transplantation tolerance. Autoimmune disorders are chronic diseases caused by the breakdown of tolerance against self-antigens. Usually they involve a specific region of the body such as the joints in rheumatoid arthritis (RA) or the pancreatic cells in type 1 diabetes mellitus (T1D). In other autoimmune diseases such as systemic lupus erythematosus (SLE) multiple areas are affected. The origin of autoimmune diseases is still a matter of debate; one hypothesis involves a failure in central and peripheral tolerance with the latter being associated with reduced Treg number or failure in their function (19). Furthermore, the combination of genetic and environmental risk factors has been implicated in the ontogenesis of autoimmunity as well (20). Similar to transplantation, immunosuppressive regimens aim to inhibit the activation of the immune system and reduce chronic inflammation. Different monoclonal antibodies targeting co-stimulatory molecules (21), cytokines (22), and lineage specific molecules (23) have been tested however, they all aim to target the immune and autoimmune responses leaving patients immunocompromised. For this reason, Tregs have been suggested as an effective tool for the treatment of autoimmune diseases. TREGS ONTOGENESIS The summation of the research over the past years has demonstrated that the thymus is the crucial organ for the generation of Tregs (24). Animal models have shown that the differentiation of thymus-derived Tregs (tTregs) depends on T cell receptor (TCR) signaling, particularly the strength and duration of the signal (25). Despite technical limitations, this has been confirmed in humans as well (24). In thymus, immature CD4 single positive (SP) cells receive a TCR signal of varied strength, which will drive their fate. Following a TCR signal of high strength, most CD4 SP cells undergo negative selection, whereas those receiving TCR signals of intermediate strength are able to escape deletion and are committed to differentiate into Tregs (26). Nevertheless, whether there are differences between TCR signals for conventional T cells (Tconv) and Tregs is still an open question. Some pieces of evidence so far support the idea of “quantitative” difference in signaling, but it is also plausible that TCR signals might be “qualitatively” different. Beyond TCR signaling, CD28 is also crucial in the generation of tTregs. In fact, both CD28–deficient and CD80-CD86-deficient mice have decreased number of Tregs (27). Several other factors, including NFAT/AP1, ICOS/ICOSL and thymic stromal lymphopoietin (TSLP) are involved in the transcriptional control of human Treg differentiation (28–30). FOXP3 expression requires the presence of γ chain cytokines (IL-2, IL-15, and IL-7) and the reduction

Read the complete text